IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER
Metastatic Intrahepatic Cholangiocarcinoma
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 29/ 100
- Competitive Position
- 95/ 100
Competitive context
38 Active assets in the Metastatic Intrahepatic Cholangiocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Virogin Biotech Canada Ltd | Phase 2 | BB |
Durvalumab West China Hospital | Phase 2 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Shanghai 6th People's Hospital | Phase 2 | BB |
Atezolizumab National Cancer Institute (NCI) | Phase 2 | B |
Irinotecan Tianjin Medical University Cancer Institute and Hospital | Phase 3 | B |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →